TABLE 1.
Baseline Characteristics
| Characteristic | THC:CBD (n = 73), No. (%) | Placebo (n = 74), No. (%) | Overall (N = 147), No. (%) |
|---|---|---|---|
| Age, years | |||
| Median (min-max) | 55 (25-76) | 59 (29-80) | 56 (25-80) |
| Sex | |||
| Female | 56 (77) | 59 (80) | 115 (78) |
| Eastern Cooperative Oncology Group status | |||
| 0-1 | 70 (96) | 73 (99) | 143 (97) |
| Previous cannabis use | |||
| Yes | 28 (38) | 30 (41) | 58 (39) |
| Alcohol (standard drinks/week) | |||
| 0 | 51 (70) | 42 (57) | 93 (63) |
| 1-7 | 22 (30) | 27 (36) | 49 (33) |
| >7 | 0 | 5 (7) | 5 (3) |
| History of motion sickness | |||
| Yes | 23 (32) | 23 (31) | 46 (31) |
| History of nausea during pregnancy | |||
| Yes | 26/50 (52) | 27/51 (53) | 53/101 (52) |
| Primary cancer site | |||
| Breast | 26 (36) | 29 (39) | 55 (37) |
| GI | 25 (34) | 20 (27) | 45 (31) |
| Lung | 9 (12) | 8 (11) | 17 (12) |
| Gynecologic | 4 (5) | 7 (9) | 11 (7) |
| Genitourinary | 3 (4) | 5 (7) | 8 (5) |
| Hematologic | 2 (3) | 3 (4) | 5 (3) |
| Sarcoma | 1 (1) | 0 | 1 (1) |
| Head and neck | 1 (1) | 0 | 1 (1) |
| Unknown primary | 2 (3) | 2 (3) | 4 (3) |
| Treatment intent | |||
| Curative | 41 (56) | 54 (73) | 95 (65) |
| Palliative | 32 (44) | 20 (27) | 52 (35) |
| Chemotherapy emetic severity | |||
| High | 36 (49) | 42 (57) | 78 (53) |
| Moderate | 37 (51) | 32 (43) | 69 (47) |
| Chemotherapy cycle duration, days | |||
| 14 | 36 (49) | 40 (54) | 76 (52) |
| 21 | 37 (51) | 34 (46) | 71 (48) |
| Chemotherapy regimen | |||
| Anthracycline-based | 20 (27) | 28 (38) | 48 (33) |
| Carboplatin-based | 13 (18) | 12 (16) | 25 (17) |
| FOLFOX ± biological | 14 (19) | 12 (16) | 26 (18) |
| Cisplatin-based | 13 (18) | 12 (16) | 25 (17) |
| FOLFIRINOX | 7 (10) | 4 (5) | 11 (7) |
| Other | 6 (8) | 6 (8) | 12 (8) |
| Background antiemetic prophylaxis | |||
| Dexamethasone | 72 (99) | 71 (96) | 143 (97) |
| 5-HT3 antagonist | 71 (97) | 72 (97) | 143 (97) |
| NK-1 antagonist | 59 (81) | 58 (78) | 117 (80) |
| Olanzapine | 7 (10) | 8 (11) | 15 (10) |
Abbreviations: 5-HT3, 5-hydroxytryptamine; CBD, cannabidiol; FOLFIRINOX, infusional fluorouracil, leucovorin, irinotecan, and oxaliplatin; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; NK-1, neurokinin-1; THC, tetrahydrocannabinol.